Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this . After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this .
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at .
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit .
Investors:
Alex Braun
Media:
